CJC-1295 No DAC Cycle Length: Studies, Breaks & Evidence Gaps

There is no evidence-based week count for a routine CJC-1295 No DAC cycle in the research reviewed here. A cycle usually means a planned course followed by time off and perhaps another course. To validate that pattern, a study would need to test the exact compound and follow both the active period and what happens after stopping.

That is a different question from whether a related peptide changes a hormone level. It is also different from how long a vial lasts or when a person notices a change in sleep. Each question needs its own evidence. Combining several incomplete answers does not create a tested schedule.

The name CJC-1295 is used loosely online. No DAC usually refers to modified GRF 1-29, a modified fragment of growth hormone-releasing hormone, or GHRH. The long-acting CJC-1295 studied in people includes an extra part that binds to albumin, a blood protein. That albumin-binding part is called DAC.

The original development paper describes albumin-linked compounds, tests in rat pituitary cells, and experiments in rats. It explains the design of long-acting CJC-1295. It does not report a multiweek human No-DAC course. A shared starting structure is not enough to make the finished products interchangeable.

The No-DAC protocol background explains terminology and calculation examples. Examples on a protocol page do not become clinical evidence for a cycle simply because the arithmetic is consistent.

Original Reddit discussions and searches for independent firsthand reports were reviewed on October 15, 2026. No suitable, clearly documented completed report of standalone, route-confirmed No-DAC use was verified for a cycle comparison. Many results concerned CJC/ipamorelin blends or switched between DAC and No DAC.

For example, a firsthand comment in a DAC-versus-No-DAC discussion describes eight- to ten-week courses of No DAC with ipamorelin, used off and on over several years. The writer describes some benefit, but not a dramatic result, and later changed to other compounds because of the burden of frequent injections. The parent post includes commercial links. This is a mixed-product account, not evidence for No DAC alone.

That account does not give a verified off-period or a controlled comparison of repeat courses. It cannot show which ingredient caused a change or what happened to people who stopped posting. The duration is included to explain the claim readers may encounter, not to turn it into a schedule or a shopping quantity.

The Teichman study reported two trials lasting 28 and 49 days in healthy adults. They tested long-acting CJC-1295, with single exposure in one study and two or three administrations in the other. The study measured drug levels, growth hormone, and IGF-1, a hormone linked to growth hormone.

The Ionescu and Frohman study found that growth hormone still rose and fell in pulses during long-acting stimulation. It did not compare DAC with No DAC. It therefore cannot support a claim that No DAC alone preserves normal pulses, produces better sleep, or needs a particular break.

A trial can include screening, treatment, blood sampling, and later safety checks. Only some of those days may involve giving the study compound. Calling the entire window an active course hides what actually happened. This is especially misleading when a long-lasting compound was given only a few times.

The difference matters even before comparing DAC with No DAC. Twenty-eight days of observation after one exposure is not the same experiment as giving something daily for 28 days. Neither tells us what happens after several rounds of stopping and restarting.

A later paper can also reuse earlier samples. The 2009 serum-protein study examined protein patterns associated with long-acting CJC-1295 exposure. Its later publication date is not evidence that people received years of additional treatment. Count exposure and participants, not just the number of papers.

Neither duration is established as a standard for standalone No DAC. Choosing between them would require evidence that compares useful outcomes and harms under those actual conditions. A longer course is not automatically better, and a shorter course is not automatically safe.

The same problem applies to claims about when results begin. Better sleep, faster recovery, muscle gain, and fat loss are separate outcomes. A hormone measurement cannot tell us when all of them appear, whether they occur at all, or how large a change matters in daily life.

A receptor is a cell's docking site for a signal. Desensitization means the response to repeated stimulation becomes weaker. That is a possible research question, not proof that a chosen break restores the response. No verified human No-DAC trial here compared weekend gaps, a four-week break, or another reset plan.

To test a reset claim, researchers would need to measure a response before the break and after restarting, while keeping other factors comparable. Feeling less of an effect is not the same measurement. Nor does a strong feeling after restarting establish better results or lower risk.

Half-life is the time for a measured drug level to fall by half. It is not the time until all effects end or a person becomes ready for another course. The often-cited multiday CJC-1295 half-life belongs to the DAC research. It cannot be assigned to No DAC.

No precise human No-DAC half-life is established by those papers. Even if that number were known, multiplying it would not establish recovery of every hormone pathway or a safe repeat schedule. Drug levels, hormone signals, symptoms, and lasting outcomes are different things.

If a clinician considers blood testing useful, they need to know the question, the exact product, other medicines, and when exposure occurred. A normal result does not validate a research product. A high or low marker also does not provide a self-directed reason to add more, extend use, or restart.

A combination becomes a separate research question. A result after using two compounds cannot tell us the benefit or risk of either one alone. Separate vials taken together create the same problem as a premixed vial: more than one active ingredient has changed.

Do not borrow an ipamorelin course, a sermorelin schedule, or the treatment duration of prescription tesamorelin to fill the No-DAC gap. Similar goals or related hormone pathways do not establish matching durations. A prescription product's clinical evidence also does not approve a research catalog product.

For comparison, see the CJC-1295 with DAC cycle guide and ipamorelin background. Their evidence should stay attached to the compound and route that were actually studied.

The FDA's CJC-1295 review separates DAC and non-DAC substances and highlights limited safety information, unclear product identity, and concerns about immune reactions. The human clinical data it discusses largely concern DAC. They do not give a reliable No-DAC side-effect rate or establish long-term safety.

An immune reaction means the body's defenses react to a substance. Peptide clumps or impurities can affect that risk. A purity result answers only the tests that were performed; it does not by itself prove sterility (freedom from contaminating germs), correct strength, stability after mixing, or suitability for human use. The FDA explains these differences for compounded drugs. Research vials are a further distinct category.

There is no approved No-DAC label that supplies a complete personal screening plan. Medical history, unexplained symptoms, pregnancy, and other medicines need professional assessment. Having no immediate symptoms does not settle long-term risk. A planned end date is not a reason to wait when new problems appear.

A useful study would name the exact No-DAC material, confirm its quality, and use a defined route in a defined group of people. It would measure meaningful benefits as well as harms. If the goal were to test cycling, it would compare the proposed breaks and follow repeated exposure.

Until then, the most practical questions are straightforward: What problem is being addressed? Is there an established treatment for it? What evidence applies to this exact product? What would lead a clinician to change the plan? These questions are more useful than choosing a course because a chart contains a familiar number of weeks.